Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 68-year-old woman is evaluated in the hospital on day 6 of an admission for a massive right lower extremity deep vein thrombosis. She has been treated with a continuous unfractionated heparin infusion since admission. Her past medical history includes hypertension, osteoarthritis, and type 2 diabetes mellitus. Today, she reports new-onset right arm pain and swelling at the site of a recently removed peripheral intravenous catheter.

Vital signs are within normal limits. Physical examination reveals a swollen, tender, and erythematous right upper extremity.

Laboratory TestPatient ResultReference Range
Hemoglobin12.4 g/dL12.0-15.5 g/dL
Platelet count85,000/mm³150,000-400,000/mm³
aPTT65 seconds60-80 seconds (therapeutic)
Serum creatinine1.1 mg/dL0.6-1.2 mg/dL

The patient's baseline platelet count on admission was 240,000/mm³.

Which of the following are appropriate next steps in the monitoring and management of this patient? (Select all that apply)

  1. Discontinue unfractionated heparin and initiate a direct thrombin inhibitorCevap
  2. Order an enzyme-linked immunosorbent assay for anti-platelet factor 4 antibodiesCevap
  3. C
    Switch the anticoagulant therapy to subcutaneous enoxaparin
  4. D
    Withhold all systemic anticoagulation until the platelet count recovers above 150,000/mm³
  5. E
    Order a serotonin release assay as the initial diagnostic test to confirm the diagnosis prior to altering therapy

Cevap

The correct steps are to immediately discontinue the unfractionated heparin, initiate a direct thrombin inhibitor, and order an enzyme-linked immunosorbent assay (ELISA) for anti-platelet factor 4 antibodies.
This patient has a classic presentation of heparin-induced thrombocytopenia (HIT), evidenced by a >50% drop in platelets occurring 5 to 10 days after heparin initiation, alongside a new thrombotic event (suspected upper extremity DVT). Because HIT is a highly prothrombotic state driven by immune-complex mediated platelet activation, all heparin exposure must end immediately, and alternative anticoagulation (such as argatroban or bivalirudin) must be started empirically without waiting for lab results. The appropriate initial diagnostic test is the highly sensitive PF4 ELISA, rather than the more specific but time-consuming serotonin release assay.

Adım Adım Çözüm

1
Calculate the 4T score to determine the clinical probability of heparin-induced thrombocytopenia (HIT).
The patient has a platelet drop >50% (2 points), timing between days 5-10 (2 points), new suspected thrombosis (2 points), and no other obvious causes (2 points), yielding a high-probability score of 8.
A high clinical suspicion dictates immediate empiric management changes before laboratory confirmation is available.
2
Select the appropriate immediate pharmacologic intervention.
Discontinue unfractionated heparin and initiate a non-heparin anticoagulant, such as a direct thrombin inhibitor (e.g., argatroban).
Continuing heparin or switching to low-molecular-weight heparin will fuel the immune-mediated platelet activation, while stopping all anticoagulation fails to protect against the high risk of new thromboses.
3
Select the appropriate initial diagnostic laboratory test to evaluate the complication.
Order a screening PF4 antibody ELISA.
The ELISA is rapid and highly sensitive, making it the ideal first-line test in the diagnostic sequence for HIT, to be followed by a confirmatory functional assay if positive.

Anahtar Kavram

Evaluation and management of Heparin-Induced Thrombocytopenia (HIT)

Alternatif Yöntem

In cases where direct thrombin inhibitors like argatroban are unavailable or contraindicated (e.g., severe hepatic impairment), fondaparinux or bivalirudin may be utilized as alternative non-heparin anticoagulants for HIT management.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru